Oral Mucositis Therapeutics Pipeline to Receive More Drug Designations from the USFDA in the Coming Years: P&S Market Research

NEW YORK, April 06, 2018 -- According to a new research report titled “Oral Mucositis Therapeutics Pipeline Analysis, 2017” published by P&S Market Research, Oral Mucositis currently exhibits a pipeline with 18 drug candidates.

Request for Sample Copy of this Research Report: https://www.psmarketresearch.com/market-analysis/oral-mucositis-therapeutics-pipeline-analysis/report-sample

The study analyzed that the oral mucositis therapeutics pipeline comprises approximately 18 drug candidates in different stages of development. Oral mucositis is the most common complication of chemotherapy in cancer patients. It causes damage to mucosal lining of the mouth which results in formation of ulcers. It can result in several problems that includes severe pain in mouth, nutritional problems as a result of inability to eat and increased risk of infection due to open sores in the mucosa.

Oragenics, Inc. is using ActoBiotics technology platform for the development of their drug candidates for the treatment of oral mucositis. The technology platform produces a new class of orally delivered biopharmaceuticals. Through ActoBiotics technology platform, food-grade microbes are engineered to generate biologically contained ActoBiotics therapeutics for in situ expression and secretion of novel proteins and peptides including cytokines, enzymes, hormones and monoclonal antibodies within the body.

Browse Full Report with detailed TOC on “Oral Mucositis Therapeutics Pipeline Analysis” at: https://www.psmarketresearch.com/market-analysis/oral-mucositis-therapeutics-pipeline-analysis

The research also found that various companies received designations from the USFDA for the development of the drugs in the oral mucositis therapeutics pipeline. In November 2016, USFDA granted Fast Track designation to AG013 for the treatment of oral mucositis.

Some of the other key players developing drugs for the treatment of oral mucositis include Daewoong Pharmaceutical Co., Ltd., Cellceutix Corporation, Soligenix, Inc. and others.

More Reports Published by P&S Market Research

HSV Infections Therapeutics Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis

COPD Therapeutics Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/copd-therapeutics-pipeline-analysis

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: [email protected]

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook